Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

new cases are expected to be diagnosed and it is estimated that approximately 8,110 people in the United Sates will die from the disease.

About IDM Pharma

IDM Pharma (IDM) is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. IDM's lead product candidate, JUNOVAN(TM) (mifamurtide for injection), known as MEPACT in Europe, is part of a new family of immunotherapeutic agents designed to destroy residual cancer cells by activating the body's natural defenses. IDM's applications requesting marketing approval of JUNOVAN for use in the treatment of newly diagnosed resectable high-grade osteosarcoma patients in combination with multiple agent chemotherapy are under review by the U.S. Food and Drug Administration, or FDA, in the United States and by the European Medicines Agency, or EMEA, in Europe. IDM is jointly developing UVIDEM, a cell-based vaccine product candidate in Phase II clinical trials for the treatment of melanoma, with sanofi-aventis. EP-2101 is currently being tested in non-small cell lung cancer (NSCLC) patients in a Phase II clinical trial and is composed of multiple tumor-specific CTL epitopes selected from tumor- associated antigens.

For more information, visit http://www.idm-pharma.com.

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's curr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

Post Your Comments:
(Date:11/6/2009)...WN, N.J., Nov. 6 Watson ...cialty pharmaceutical company, announced today tha...ive officer, will provide an overview and update o... Annual Healthcare Conference on Wednesday, Novemb..., This presentation will be webcast live and can ...
(Date:11/6/2009)...ON, S.C., Nov. 6 The ...n South Carolina and Georgia throughout the week o... uninsured and financially-struggling patients acc...ion medicines for free or nearly free. With the na... the Partnership for Prescription Assistance (PPA)...
(Date:11/6/2009)...Mass., Nov. 6 Boston Sci...that it has reached an agreement in principle with...roduct advisories issued by its Guidant subsidiary...ccurred prior to Boston Scientific,s 2006 acquisit...usly disclosed an investigation by the U.S. Attorn...
Breaking Medicine Technology:Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Screening for Cardiovascular Diseases Difficult but Necessary 60379 1Screening for Cardiovascular Diseases Difficult but Necessary 60379 2Skiing Not As Dangerous as Believed 60375 1Skiing Not As Dangerous as Believed 60375 2Skiing Not As Dangerous as Believed 60375 3Skiing Not As Dangerous as Believed 60375 4Emerging imaging modalities impact diagnosis of digestive disease 60371 1Emerging imaging modalities impact diagnosis of digestive disease 60371 2Emerging imaging modalities impact diagnosis of digestive disease 60371 3Emerging imaging modalities impact diagnosis of digestive disease 60371 4
... IDM Pharma, Inc.,(Nasdaq: IDMI ) today announce...e for Medicinal Products for Human Use (CHMP) and ...) on September 25th, following the,CHMP,s Septembe...eting,Authorization Application (MAA) for mifamurt...non-metastatic, resectable osteosarcoma, a rare,an...
...ective Effect of Quark,s New RNAi Product on,Dying...laucoma, FREMONT, Calif., Sept. 25 Quark Pharmac...company discovering and developing novel,RNA inter... QPI-1007 as the,Company,s first siRNA drug candid...ost of novel structures having freedom to operate ...
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property 2Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property 3
(Date:11/7/2009)...ire-USNewswire/ -- Speaker Nancy Pelosi spoke on ... Affordable Health Care for America Act. The Hous...ow are the Speaker,s remarks. ,, "Madam Speake...r our nation and for American families. For nearl...philosophy -- as far back as Teddy Roosevelt -- ha...
(Date:11/7/2009)...vid A. Cook (GA), Louis J. Goodman (TX), Palmer P....HICAGO, Nov. 7 The Amer...e medical society executive leaders with achieveme...s and ideals of the medical profession. The awards...king meeting in Houston. ,, (Logo: http://ww...
(Date:11/7/2009)...-USNewswire/ -- With the final House vote on healt...lding the entire bill hostage to further their ant... go far beyond the status quo restrictions on abor...bill. In an outrageous amendment, which is expect...oice Democrats are demanding explicit and unequivo...
(Date:11/7/2009)...-USNewswire/ -- Speaker Nancy Pelosi and Democrati... following a Democratic Whip meeting with Presiden...Speaker,s opening remarks: ,, "Thank you very ...us to receive the President of the United States o... vote and making progress for the American people....
(Date:11/7/2009)...th will rebel, expert says , , SATURDAY, N... behave badly if their parents expect them to, a n...ey are simply being realistic might actually contr...anan, a psychology professor at Wake Forest Univer...ity news release. "Negative expectations on the pa...
Breaking Medicine News(10 mins):Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA Honors Medical Society Executives 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2
...w Year,s Resolution to focus on health by using th...program , , ORLANDO, Fla., Feb. 12 Over 2.6 mi... those currently unemployed also find themselves w...s in household budgets. Unfortunately, some people...
...OLA, Calif., Feb. 12 Fisher Vista, LLC, a marketi...enior care and human resource,industries today ann...company,for seven years, has been named president ...roup. Mr. Grossman will continue,to report to Mar...
...h enzastaurin, even tumors that did develop weren,...eb. 12 (HealthDay News) -- A drug called enzastaur...cancer in mice, and tumors that did develop were l...findings, coupled with the fact that the drug appe...
... and CEO, Scott Grisanti, Publishes Letter Outlini... Team , , BETHEL, Conn., Feb. 12 MedClean Techno...r of innovative technology and services for the on...ders. The letter, which is available on the Compa...
..., Feb. 12 After Phil Cohen, president of Clevelan...e interview last year, he signed on to do three mo...lly introduced those videos this week via PRN Fund...g,s three featured factoring educational videos ar...
...Dispels Myths Surrounding Essential Fat , , ST. L...rican Heart Association (AHA) concludes that omega... when part of a healthy eating plan. Omega-6s are ...ation leading to heart disease, the nation,s numbe...
Other Medicine News:Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 2Health News:During Tough Economic Times Remember Your Health - Save With Your AAA Membership on Necessities From Prescriptions to Eyeglasses 3Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Drug Inhibits Colon Cancer in Mice 2Health News:MedClean Technologies Inc. CEO Publishes Letter to Shareholders 2Health News:PRN Funding Introduces the PRN Funding YouTube Channel 2Health News:American Heart Association Finds Omega-6 Fatty Acids in Soybean Oil Are Heart-Healthy 2Health News:American Heart Association Finds Omega-6 Fatty Acids in Soybean Oil Are Heart-Healthy 3
Vitek 2
Vitek
IDS Rapid Yeast Plus
IDS Rapid SS/u
Medicine Products: